+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
RNA Therapy Market - Global Forecast 2026-2032- Product Image
RNA Therapy Market - Global Forecast 2026-2032- Product Image
New

RNA Therapy Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 184 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968964
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The RNA therapy market is entering a pivotal phase, characterized by rapid scientific developments, multiple delivery technologies, and evolving regulatory environments. Senior decision-makers face complex decisions as they seek to maximize growth, manage risk, and drive operational agility across an increasingly sophisticated landscape.

Market Snapshot: RNA Therapy Market 2025–2032

The RNA therapy market is projected to expand from USD 18.77 billion in 2025 to USD 19.70 billion in 2026, maintaining steady growth at a CAGR of 6.40% toward USD 28.99 billion by 2032. Expansion is supported by consistent clinical evidence, redefined supply chain strategies, and marked increases in regional investment. Industry players are consolidating strategic advantages by leveraging next-generation RNA modalities, allowing for adaptable product portfolios and commercialization strategies. The surge in demand for personalized medicine is shaping product innovation and necessitating robust infrastructure to support scaling and access. This underscores the need for a clear strategic approach as the RNA therapy market continues integrating with the broader biopharmaceutical sector.

Scope & Segmentation of the RNA Therapy Market

  • Therapeutic Areas: Includes applications spanning cardiovascular illnesses, genetic disorders, infectious diseases (encompassing both bacterial and viral origins), metabolic and neurological diseases, and prominent oncology targets like hematological malignancies and solid tumors. The segment also addresses rare conditions such as Gaucher disease, neuromuscular disorders, and sickle cell disease, illustrating the broadening reach of RNA-based approaches in modern therapeutics.
  • Delivery Platforms: Covers a spectrum of mechanisms including exosomes, lipid nanoparticles, polymer carriers, and viral vectors. Each technology distinctly influences targeting ability, immune profile, production scale, and timing of clinical trials, allowing programs to align delivery methods with specific development objectives.
  • End-User Groups: Comprises biotechnology companies, pharmaceutical manufacturers, hospitals and clinics, and academic or research institutes. The needs of these groups guide commercialization strategy, facility investments, and time-to-market considerations, resulting in a highly diverse and dynamic market ecosystem.
  • Geographic Regions: Assesses the Americas, Europe Middle East & Africa, and Asia-Pacific, each with specific regulatory challenges, adoption curves, and infrastructure capacities. Multinational development teams must navigate distinctive regional nuances in technology uptake, trials, and market penetration.

Key Takeaways: Strategic Considerations in RNA Therapeutics

  • RNA platforms have evolved from research concepts to clinically validated therapies, fueled by new molecular engineering methods and production advancements.
  • Success is influenced equally by scientific innovation, effective delivery platform selection, resilient supply chain strategies, and partnerships between technology providers and healthcare institutions.
  • Strategic differentiation increasingly depends on aligning delivery technologies and pipeline priorities to meet shifting program requirements and competitive pressures.
  • Synergistic relationships between emerging biotechnology firms and established pharmaceutical partners accelerate clinical adoption and streamline operational and regulatory integration.
  • Growing end-user expectations, including faster production cycles for infectious diseases and targeted approaches for rare conditions, are refocusing commercialization strategies and shaping capital allocation.
  • Varying regional factors—such as evolving policies in Asia-Pacific and payer complexities in Europe, the Middle East & Africa—directly impact commercialization decisions, reimbursement, and access planning.

Tariff Impact: U.S. Trade Policy and RNA Supply Chains

Ongoing changes to United States tariffs are altering sourcing for essential materials and equipment in the RNA therapy supply chain. To minimize disruption, stakeholders are expanding supplier bases, shifting procurement to domestic sources, and refining logistics. While these adjustments may increase short-term complexity, they support long-term supply chain resilience, drive investment in local manufacturing, and help ensure continuity in RNA-related product delivery.

RNA Therapy Market Methodology & Data Sources

This analysis utilizes a triangulated research approach that balances peer-reviewed scientific literature, regulatory updates, corporate disclosures, and expert interviews. Validity is strengthened by cross-checking real-world evidence, conducting stakeholder analyses, and performing comparative case reviews to deliver actionable insights for senior leaders.

Why This Report Matters for Decision-Makers

  • Provides structured prioritization of RNA therapy pipelines and delivery technologies, clarifying the impact of platform choices and therapeutic focus areas.
  • Enables adaptation of regulatory and supply chain strategy in response to evolving policy conditions, supporting operational agility in a global setting.
  • Facilitates sound planning for commercial partnerships, manufacturing expansion, and payer engagement, aligning with both strategic and patient access objectives.

Conclusion: Strategic Imperatives for RNA Therapeutics

Effective growth in the RNA therapy sector demands integration of scientific progress and robust supply chains, together with informed engagement of payers. Organizations committed to these principles are positioned to advance access and deliver sustainable results within evolving healthcare frameworks.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. RNA Therapy Market, by Therapeutic Area
8.1. Cardiovascular Diseases
8.2. Genetic Disorders
8.3. Infectious Diseases
8.3.1. Bacterial Infections
8.3.2. Viral Infections
8.4. Metabolic Disorders
8.5. Neurological Disorders
8.6. Oncology
8.6.1. Hematological Malignancies
8.6.2. Solid Tumors
8.7. Rare Diseases
8.7.1. Gaucher Disease
8.7.2. Neuromuscular Disorders
8.7.3. Sickle Cell Disease
9. RNA Therapy Market, by Delivery System
9.1. Exosomes
9.2. Lipid Nanoparticles
9.3. Polymer Carriers
9.4. Viral Vectors
10. RNA Therapy Market, by End User
10.1. Biotechnology Companies
10.2. Hospitals & Clinics
10.3. Pharmaceutical Companies
10.4. Research Institutes
11. RNA Therapy Market, by Region
11.1. Americas
11.1.1. North America
11.1.2. Latin America
11.2. Europe, Middle East & Africa
11.2.1. Europe
11.2.2. Middle East
11.2.3. Africa
11.3. Asia-Pacific
12. RNA Therapy Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. RNA Therapy Market, by Country
13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea
14. United States RNA Therapy Market
15. China RNA Therapy Market
16. Competitive Landscape
16.1. Market Concentration Analysis, 2025
16.1.1. Concentration Ratio (CR)
16.1.2. Herfindahl Hirschman Index (HHI)
16.2. Recent Developments & Impact Analysis, 2025
16.3. Product Portfolio Analysis, 2025
16.4. Benchmarking Analysis, 2025
16.5. Alnylam Pharmaceuticals, Inc.
16.6. Arcturus Therapeutics Holdings, Inc.
16.7. Arrowhead Pharmaceuticals, Inc.
16.8. BioNTech SE
16.9. CureVac N.V.
16.10. Eli Lilly and Company
16.11. Ionis Pharmaceuticals, Inc.
16.12. Moderna, Inc.
16.13. Sarepta Therapeutics, Inc.
16.14. Silence Therapeutics plc
16.15. Stoke Therapeutics
List of Figures
FIGURE 1. GLOBAL RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL RNA THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL RNA THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. UNITED STATES RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 11. CHINA RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS RNA THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 103. EUROPE RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. EUROPE RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 105. EUROPE RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 106. EUROPE RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 107. EUROPE RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 108. EUROPE RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 109. EUROPE RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. MIDDLE EAST RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. MIDDLE EAST RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 112. MIDDLE EAST RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 114. MIDDLE EAST RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 115. MIDDLE EAST RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 117. AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. AFRICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 119. AFRICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 120. AFRICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 121. AFRICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 122. AFRICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 123. AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL RNA THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. ASEAN RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. ASEAN RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 134. ASEAN RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 135. ASEAN RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 136. ASEAN RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 137. ASEAN RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 138. ASEAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 139. GCC RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. GCC RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 141. GCC RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 142. GCC RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 143. GCC RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 144. GCC RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 145. GCC RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 148. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 150. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 151. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 152. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 153. BRICS RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. BRICS RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 155. BRICS RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 156. BRICS RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 157. BRICS RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 158. BRICS RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 159. BRICS RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. G7 RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 161. G7 RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 162. G7 RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 163. G7 RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 164. G7 RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 165. G7 RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 166. G7 RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. NATO RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 168. NATO RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 169. NATO RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 170. NATO RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 171. NATO RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 172. NATO RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 173. NATO RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 174. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. UNITED STATES RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 176. UNITED STATES RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 177. UNITED STATES RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 178. UNITED STATES RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 179. UNITED STATES RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 180. UNITED STATES RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 181. UNITED STATES RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. CHINA RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 183. CHINA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 184. CHINA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 185. CHINA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 186. CHINA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 187. CHINA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 188. CHINA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this RNA Therapy market report include:
  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics Holdings, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • BioNTech SE
  • CureVac N.V.
  • Eli Lilly and Company
  • Ionis Pharmaceuticals, Inc.
  • Moderna, Inc.
  • Sarepta Therapeutics, Inc.
  • Silence Therapeutics plc
  • Stoke Therapeutics

Table Information

Report AttributeDetails
No. of Pages184
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 19.7 Billion
Forecasted Market Value ( USD ) by 2032 $ 28.99 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

RNA Interference Technology Market - Global Forecast 2026-2032 - Product Image

RNA Interference Technology Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
RNA-based Therapeutics - Global Strategic Business Report - Product Image

RNA-based Therapeutics - Global Strategic Business Report

  • Report
  • 274 Pages
  • Global
From
Ribonucleic Acid (RNA) Therapy Clinical Trials Market Report 2025 - Product Image

Ribonucleic Acid (RNA) Therapy Clinical Trials Market Report 2025

  • Report
  • 250 Pages
  • Global
From
RNA Therapy Clinical Trials Market - Global Strategic Business Report - Product Image

RNA Therapy Clinical Trials Market - Global Strategic Business Report

  • Report
  • 244 Pages
  • Global
From
RNA Interference Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

RNA Interference Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 140 Pages
  • Global
From

About the RNA Therapy Market

RNA therapy is a form of gene therapy that uses RNA molecules to treat or prevent diseases. It is a type of genomics-based therapy that works by introducing genetic material into cells to modify their behavior. RNA therapy can be used to treat a variety of diseases, including cancer, neurological disorders, and infectious diseases. It has the potential to be used to treat genetic disorders, as well as to modify the expression of genes in order to improve the effectiveness of existing treatments. RNA therapy works by introducing genetic material into cells, which can then be used to modify the expression of genes. This can be done by introducing a gene that produces a therapeutic protein, or by introducing a gene that silences a gene that is causing a disease. RNA therapy can also be used to modify the expression of existing genes, which can be used to improve the effectiveness of existing treatments. RNA therapy is an emerging field of genomics-based therapy, and is being explored by a number of companies. Examples of companies in the RNA therapy market include Moderna, BioNTech, and Arcturus Therapeutics. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.